Motzer RJ - Search Results

1

PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.

Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B, George DJ, Motzer RJ, Morris MJ, Powles T, Wang E, Huang Y, Freeman GJ, Choueiri TK, Signoretti S. Flaifel A, et al. Among authors: motzer rj. Clin Cancer Res. 2019 Oct 15;25(20):6080-6088. doi: 10.1158/1078-0432.CCR-19-1135. Epub 2019 Aug 1. Clin Cancer Res. 2019. PMID: 31371341 Free PMC article.

2

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.

Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, Reuter V, Tong WP, Iversen J, Louison C, Albino AP, et al. Motzer RJ, et al. Cancer Res. 1992 Oct 15;52(20):5775-9. Cancer Res. 1992. PMID: 1394202 Clinical Trial.

3

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.

Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, Nanus D, O'Moore P, Marathias K, Bosl GJ. Ilson DH, et al. Among authors: motzer rj. J Clin Oncol. 1992 Jul;10(7):1124-30. doi: 10.1200/JCO.1992.10.7.1124. J Clin Oncol. 1992. PMID: 1607918 Clinical Trial.

4

Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.

Murphy BA, Motzer RJ, Mazumdar M, Vlamis V, Nisselbaum J, Bajorin D, Bosl GJ. Murphy BA, et al. Among authors: motzer rj. Cancer. 1994 May 15;73(10):2520-6. doi: 10.1002/1097-0142(19940515)73:10<2520::aid-cncr2820731012>3.0.co;2-r. Cancer. 1994. PMID: 7513603

5

Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.

Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM. Motzer RJ, et al. J Clin Oncol. 1995 Aug;13(8):1950-7. doi: 10.1200/JCO.1995.13.8.1950. J Clin Oncol. 1995. PMID: 7636535 Clinical Trial.

6

Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.

Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C, O'Brien JP. Motzer RJ, et al. J Clin Oncol. 1995 Aug;13(8):1958-65. doi: 10.1200/JCO.1995.13.8.1958. J Clin Oncol. 1995. PMID: 7636536 Clinical Trial.

7

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.

Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Minasian LM, et al. Among authors: motzer rj. J Clin Oncol. 1993 Jul;11(7):1368-75. doi: 10.1200/JCO.1993.11.7.1368. J Clin Oncol. 1993. PMID: 8315435 Clinical Trial.

8

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.

Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF. Law TM, et al. Among authors: motzer rj. Cancer. 1995 Sep 1;76(5):824-32. doi: 10.1002/1097-0142(19950901)76:5<824::aid-cncr2820760517>3.0.co;2-n. Cancer. 1995. PMID: 8625186 Clinical Trial.

9

Renal-cell carcinoma.

Motzer RJ, Bander NH, Nanus DM. Motzer RJ, et al. N Engl J Med. 1996 Sep 19;335(12):865-75. doi: 10.1056/NEJM199609193351207. N Engl J Med. 1996. PMID: 8778606 Review. No abstract available.

10

Renal cell carcinoma.

Motzer RJ, Russo P, Nanus DM, Berg WJ. Motzer RJ, et al. Curr Probl Cancer. 1997 Jul-Aug;21(4):185-232. doi: 10.1016/s0147-0272(97)80007-4. Curr Probl Cancer. 1997. PMID: 9285186 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

604 results

Search Page